New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:29 EDTKBIO, OMER, ATNM, TGTX, HZNP, FPRX, DRNA, ZIOP, EBIO, RGDO, ESPRBioCentury to hold a conference
Future Leaders in the Biotech Industry Conference is being held in New York on March 28.
News For ATNM;RGDO;FPRX;OMER;EBIO;HZNP;KBIO;ZIOP;TGTX;ESPR;DRNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 17, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $38 from $31 at Piper Jaffray
Subscribe for More Information
07:11 EDTHZNPHorizon Pharma Q1 results to beat expectations by wide margin, says Stifel
Stifel believes that Horizon Pharma is benefiting from strong prescription trends, and the firm says its view was bolstered by an update on prescriptions that the company gave earlier this week. Stifel raised its price target on the stock to $40 from $30 and keeps a Buy rating on the shares.
07:03 EDTHZNPHorizon Pharma receives Notice of Allowance from USPTO for Pennsaid
Subscribe for More Information
05:51 EDTHZNPStocks with implied volatility movement; ALU HZNP
Subscribe for More Information
April 16, 2015
12:21 EDTEBIOEleven Biotherapeutics presents positive Phase 2 clinical data for EBI-005
Subscribe for More Information
09:18 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
April 15, 2015
18:51 EDTHZNPHorizon Pharma 15.35M share Secondary priced at $28.25
Subscribe for More Information
12:33 EDTZIOPStocks with call strike movement; ZIOP AVP
Ziopharm (ZIOP) October 14 call option implied volatility increased 8% to 97, Avon Products (AVP) July 11 call option implied volatility decreased 2% to 57 according to IVolatility.
07:06 EDTATNMActinium Pharmaceuticals doses first patient in final cohort of Actimab-A trial
Subscribe for More Information
05:51 EDTZIOPStocks with implied volatility movement; ZIOP MNKD
Subscribe for More Information
April 14, 2015
14:43 EDTFPRXFive Prime management to meet with Jefferies
Meeting to be held in New York on April 14 hosted by Jefferies.
11:36 EDTZIOPZiopharm cancels out of two meetings, Bloomberg reports
Subscribe for More Information
07:08 EDTOMEROmeros' OMS721 receives European approval for compassionate use
Subscribe for More Information
April 13, 2015
19:18 EDTHZNPOn The Fly: After Hours Movers
Subscribe for More Information
16:45 EDTHZNPHorizon Pharma says Duexis prescriptions up 42% in first 12 weeks of 2015
Subscribe for More Information
16:03 EDTHZNPHorizon Pharma files to sell 12M shares of common stock
Citigroup, Jefferies LLC, Cowen and Company, LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for this offering.
April 10, 2015
09:16 EDTHZNPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Quantum (QTM), up 22.2%. ALSO HIGHER: General Electric (GE), up 6.6% after announcing that it will sell most of GE Capital assets for approximately $26.5B... Horizon Pharma (HZNP), up 3.7% after receiving fast track designation for Actimmune... Tekmira Pharmaceuticals (TKMR), up 2.3% after FDA modifies partial clinical hold on Tekmira TKM-Ebola IND... Netflix (NFLX), up 2.9% after being upgraded to Buy from Neutral at Citigroup... Blackstone Mortgage Trust (BXMT), up 3.6% after acquiring $4.6B loan portfolio from GE Capital. LOWER: Citrix Systems (CTXS), down 5.8% after lowering first quarter guidance... Uniqure (QURE), down 2.4% after 3M share Secondary priced at $29.50... FIS (FIS), down 2.5% after lowering first quarter guidance... Golub Capital (GBDC), down 2.3% after 3.5M share Spot Secondary priced at $17.42.
08:02 EDTDRNADicerna announces new data for CTTNB1 DsiRNA data
Subscribe for More Information
07:02 EDTHZNPHorizon Pharma receives FDA fast track designation for Actimmune
Horizon Pharma announced the FDA granted Fast Track designation for Actimmune in the treatment of Friedreich's ataxia, or FA, a degenerative neuro-muscular disorder. The company submitted the Investigational New Drug, or IND, application for Actimmune in the treatment of FA in February and announced plans to begin a Phase 3 study in the second quarter in collaboration with the Friedreich's Ataxia Research Alliance, or FARA, and a sub-set of FARA's Collaborative Clinical Research Network, or CCRN, study centers in FA.
April 7, 2015
07:15 EDTHZNPHorizon Pharma management to meet with UBS
Meetings to be held in Austin/Houston on April 7 hosted by UBS.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use